New eye drug targets fluid buildup to fight glaucoma
NCT ID NCT07675824
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests an experimental drug called REGN22530 in people with primary open angle glaucoma or ocular hypertension. The drug is designed to block a protein in the eye that causes fluid buildup and high pressure. Researchers are checking for side effects, how the drug moves through the body, and whether it lowers eye pressure effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN22530
- What this could lead to
- If successful, this drug could offer a new way to lower eye pressure and help control glaucoma or ocular hypertension, potentially reducing the need for daily eye drops.
- What could go wrong
- This is an early-phase trial, so the drug may not work as expected or could cause side effects. It is not a cure, and long-term safety and effectiveness are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION (OHT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily reading drill restore lost reading skills in glaucoma?
- New surgical tool aims to lower eye pressure in glaucoma patients
- Could removing preservatives from glaucoma drops save Patients' eyes?
- New Preservative-Free eye drop could match leading glaucoma treatment
- Texting your way to better glaucoma care: new trial tests daily reminders
- Peeking inside the eye: ultrasound reveals how glaucoma surgery heals